اخبار و اعلانات

 آمار

تعداد نشریات283
تعداد نشریات سازمان81
تعداد شماره‌ها2,722
تعداد مقالات31,007
تعداد مشاهده مقاله26,932,868
تعداد دریافت فایل اصل مقاله16,145,528
Oso, B., Olaoye, I., Ogidi, C.. (1400). In silico Design of a Vaccine Candidate for SAR S-CoV-2 Based on Multiple T-cell and B-cell Epitopes. سامانه مدیریت نشریات علمی, 76(5), 1191-1202. doi: 10.22092/ari.2020.351605.1526
B. J Oso; I. F Olaoye; C. O Ogidi. "In silico Design of a Vaccine Candidate for SAR S-CoV-2 Based on Multiple T-cell and B-cell Epitopes". سامانه مدیریت نشریات علمی, 76, 5, 1400, 1191-1202. doi: 10.22092/ari.2020.351605.1526
Oso, B., Olaoye, I., Ogidi, C.. (1400). 'In silico Design of a Vaccine Candidate for SAR S-CoV-2 Based on Multiple T-cell and B-cell Epitopes', سامانه مدیریت نشریات علمی, 76(5), pp. 1191-1202. doi: 10.22092/ari.2020.351605.1526
Oso, B., Olaoye, I., Ogidi, C.. In silico Design of a Vaccine Candidate for SAR S-CoV-2 Based on Multiple T-cell and B-cell Epitopes. سامانه مدیریت نشریات علمی, 1400; 76(5): 1191-1202. doi: 10.22092/ari.2020.351605.1526

In silico Design of a Vaccine Candidate for SAR S-CoV-2 Based on Multiple T-cell and B-cell Epitopes

Archives of Razi Institute
مقاله 7، دوره 76، شماره 5، بهمن و اسفند 2021، صفحه 1191-1202    اصل مقاله (668.5 K)
نوع مقاله: Original Articles
شناسه دیجیتال (DOI): 10.22092/ari.2020.351605.1526
نویسندگان
B. J Oso1؛ I. F Olaoye* 1، 2؛ C. O Ogidi3
1Department of Biochemistry, McPherson University, Seriki Sotayo, Ogun State, Nigeria
2Biotechnology Unit, Department of Biological Sciences, Kings University, Odeomu, Nigeria
3School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool, England
چکیده
Coronaviruses (2019-nCoV) are large single-stranded RNA viruses that usually cause respiratory infections with a crude lethality ratio of 3.8% and high levels of transmissibility. There is yet no applicable clinical evaluation to assess the efficacy of various therapeutic agents that have been suggested as investigational drugs against the viruses despite their respective supposed hypothetical claims due to their antiviral potentials. Moreover, the development of a safe and effective vaccine has been suggested as an intervention to control the 2019-nCoV pandemic. However, a major concern in the development of a 2019-nCoV vaccine is the possibility of stimulating a corresponding immune response without enhancing the induction of the disease and associated side effects. The present investigation was carried out by predicting the antigenicity of the primary sequences of 2019-nCoV structural proteins and identification of B-cell and T-cell epitopes through the Bepipred and PEPVAC servers, respectively. The peptides of the vaccine construct include the selected epitopes based on the VaxiJen score with a threshold of 1.0 and β-defensinas an adjuvant. The putative binding of the vaccine constructs to intracellular toll-like receptors (TLRs) was assessed through molecular docking analysis and molecular dynamics simulations. The selected epitopes for the final vaccine construct are DPNFKD, SPLSLN, and LELQDHNE as B-cell epitopes and EPKLGSLVV, NFKDQVILL, and SSRSSSRSR as T-cell epitopes. The molecular docking analysis showed the vaccine construct could have favorable interactions with TLRs as indicated by the negative values of the computed binding energies. The constructed immunogen based on the immune informatics study could be employed in the strategy to develop potential vaccine candidates against 2019-nCoV.
کلیدواژه‌ها
2019-nCoV؛ Epitope؛ Immunity؛ Immunoinformatics؛ Vaccine
سایر فایل های مرتبط با مقاله
مراجع
  1. Korsman SNJ, van Zyl GU, Nutt L, Andersson MI, Preiser W. Human coronaviruses. In: Korsman SNJ, van Zyl GU, Nutt L, Andersson MI, Preiser W, editors. Virology. Edinburgh: Churchill Livingstone; 2012. p. 94-5.
  2. Ye ZW, Yuan S, Yuen KS, Fung SY, Chan CP, Jin DY. Zoonotic origins of human coronaviruses. Int J Biol Sci. 2020;16(10):1686-97.
  3. Wu C, Liu Y, Yang Y, Zhang P, Zhong W, Wang Y, et al. Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm Sin B. 2020;10(5):766-88.
  4. Chen J. Pathogenicity and transmissibility of 2019-nCoV-A quick overview and comparison with other emerging viruses. Microbes Infect. 2020;22(2):69-71.
  5. Liu T, Hu J, Xiao J, He G, Kang M, Rong Z, et al. Time-varying transmission dynamics of Novel Coronavirus Pneumonia in China. BioRxiv. 2020.
  6. WHO. Coronavirus disease 2019 (COVID-19): situation report, 73. Geneva: World Health Organization; 2020 2020-04-02.
  7. Cinatl J, Morgenstern B, Bauer G, Chandra P, Rabenau H, Doerr HW. Glycyrrhizin, an active component of liquorice roots, and replication of SARS-associated coronavirus. Lancet. 2003;361(9374):2045-6.
  8. Wu C-J, Jan J-T, Chen C-M, Hsieh H-P, Hwang D-R, Liu H-W, et al. Inhibition of severe acute respiratory syndrome coronavirus replication by niclosamide. Antimicrob Agents Chemother. 2004;48(7):2693-6.
  9. Dhama K, Sharun K, Tiwari R, Dadar M, Malik YS, Singh KP, et al. COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics. Hum Vaccin Immunother. 2020;16(6):1232-8.
  10. Greenwood B. The contribution of vaccination to global health: past, present and future. Philos Trans R Soc Lond B Biol Sci. 2014;369(1645):20130433.
  11. Enjuanes L, Dediego ML, Alvarez E, Deming D, Sheahan T, Baric R. Vaccines to prevent severe acute respiratory syndrome coronavirus-induced disease. Virus Res. 2008;133(1):45-62.
  12. Lamirande EW, DeDiego ML, Roberts A, Jackson JP, Alvarez E, Sheahan T, et al. A live attenuated severe acute respiratory syndrome coronavirus is immunogenic and efficacious in golden Syrian hamsters. J Virol. 2008;82(15):7721-4.
  13. Lokugamage KG, Yoshikawa-Iwata N, Ito N, Watts DM, Wyde PR, Wang N, et al. Chimeric coronavirus-like particles carrying severe acute respiratory syndrome coronavirus (SCoV) S protein protect mice against challenge with SCoV. Vaccine. 2008;26(6):797-808.
  14. Zhou Z, Post P, Chubet R, Holtz K, McPherson C, Petric M, et al. A recombinant baculovirus-expressed S glycoprotein vaccine elicits high titers of SARS-associated coronavirus (SARS-CoV) neutralizing antibodies in mice. Vaccine. 2006;24(17):3624-31.
  15. Perlman S, Dandekar AA. Immunopathogenesis of coronavirus infections: implications for SARS. Nat Rev Immunol. 2005;5(12):917-27.
  16. Lu X, Chen Y, Bai B, Hu H, Tao L, Yang J, et al. Immune responses against severe acute respiratory syndrome coronavirus induced by virus-like particles in mice. Immunology. 2007;122(4):496-502.
  1. Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell. 2020;181(2):281-92 e6.
  2. Doytchinova IA, Flower DR. VaxiJen: a server for prediction of protective antigens, tumour antigens and subunit vaccines. BMC Bioinform. 2007;8:4.
  3. Larsen JEP, Lund O, Nielsen M. Improved method for predicting linear B-cell epitopes. Immun Res. 2006;2(1):1-7.
  4. Ponomarenko JV, Bourne PE. Antibody-protein interactions: benchmark datasets and prediction tools evaluation. BMC Struct Biol. 2007;7(1):1-19.
  5. Gupta S, Kapoor P, Chaudhary K, Gautam A, Kumar R, Open Source Drug Discovery C, et al. In silico approach for predicting toxicity of peptides and proteins. PLoS One. 2013;8(9):e73957.
  6. Artimo P, Jonnalagedda M, Arnold K, Baratin D, Csardi G, de Castro E, et al. ExPASy: SIB bioinformatics resource portal. Nucleic Acids Res. 2012;40:W597-603.
  7. Reche PA, Reinherz EL. PEPVAC: a web server for multi-epitope vaccine development based on the prediction of supertypic MHC ligands. Nucleic Acids Res. 2005;33:W138-42.
  8. Yang J, Zhang Y. I-TASSER server: new development for protein structure and function predictions. Nucleic Acids Res. 2015;43(W1):W174-81.
  9. Benkert P, Biasini M, Schwede T. Toward the estimation of absolute quality of individual protein structure models. Bioinformatics. 2011;27:343-50.
  10. Laskowski RA, MacArthur MW, Moss DS, Thornton JM. PROCHECK: a program to check the stereochemical quality of protein structures. J Appl Crystallogr. 1993;26(2):283-91.
  11. Laskowski RA, Rullmann JAC, MacArthur MW, Kaptein R, Thornton JM. AQUA and PROCHECK-NMR: Programs for checking the quality of protein structures solved by NMR. J Biomol NMR. 1996;8(4):477-86.
  12. Weng G, Wang E, Wang Z, Liu H, Zhu F, Li D, et al. HawkDock: a web server to predict and analyze the protein-protein complex based on computational docking and MM/GBSA. Nucleic Acids Res. 2019;47.
  13. Lopez-Blanco JR, Aliaga JI, Quintana-Orti ES, Chacon P. iMODS: internal coordinates normal mode analysis server. Nucleic Acids Res. 2014;42(Web Server issue):W271-6.
  14. Lei Y, Zhao F, Shao J, Li Y, Li S, Chang H, et al. Application of built-in adjuvants for epitope-based vaccines. Peer J. 2019;6:e6185.
  15. Momtaz F, Foysal J, Rahman MM, Fotedar R. Design of Epitope Based Vaccine against Shrimp White Spot Syndrome Virus (WSSV) by Targeting the Envelope Proteins: an Immunoinformatic Approach. Turkish J Fish Aquat Sci. 2018;19:149-59.
  16. Sanchez-Trincado JL, Gomez-Perosanz M, Reche PA. Fundamentals and Methods for T- and B-Cell Epitope Prediction. J Immunol Res. 2017;2017:2680160.
  17. Gaudino SJ, Kumar P. Cross-Talk Between Antigen Presenting Cells and T Cells Impacts Intestinal Homeostasis, Bacterial Infections, and Tumorigenesis. Front Immunol. 2019;10:360.
  18. Ho NI, Huis In 't Veld LGM, Raaijmakers TK, Adema GJ. Adjuvants Enhancing Cross-Presentation by Dendritic Cells: The Key to More Effective Vaccines? Front Immunol. 2018;9:2874.
  19. Zhao L, Zhang M, Cong H. Advances in the study of HLA-restricted epitope vaccines. Hum Vaccin Immunother. 2013;9(12):2566-77.
  20. European centre for disease control. Rapid Risk Assessment: Coronavirus disease 2019(COVID-19) in the EU/EEA and the UK- ninth update. 2020.
  21. Meher PK, Sahu TK, Gahoi S, Rao AR. ir-HSP: Improved Recognition of Heat Shock Proteins, Their Families and Sub-types Based On g-Spaced Di-peptide Features and Support Vector Machine. Front Genet. 2017;8:235.
  22. Sharma R, Bayarjargal M, Tsunoda T, Patil A, Sharma A. MoRFPred-plus: Computational Identification of MoRFs in Protein Sequences using Physicochemical Properties and HMM profiles. J Theor Biol. 2018;437:9-16.
  23. Goulopoulou S, McCarthy CG, Webb RC. Toll-like Receptors in the Vascular System: Sensing the Dangers Within. Pharmacol Rev. 2016;68(1):142-67.
  24. Takeda K, Akira S. Toll-like receptors in innate immunity. Int Immunol. 2005;17(1):1-14.
  25. Chen F, Liu H, Sun H, Pan P, Li Y, Li D, et al. Assessing the performance of the MM/PBSA and MM/GBSA methods. 6. Capability to predict protein-protein binding free energies and re-rank binding poses generated by protein-protein docking. Physical chemistry chemical physics : PCCP. 2016;18(32):22129-39.
  26. Genheden S, Ryde U. The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities. Expert Opin Drug Discov. 2015;10(5):449-61.
  1. Dobbins SE, Lesk VI, Sternberg MJ. Insights into protein flexibility: The relationship between normal modes and conformational change upon protein-protein docking. Proc Natl Acad Sci U S A. 2008;105(30):10390-5.
  2. Kovacs JA, Chacon P, Abagyan R. Predictions of protein flexibility: first-order measures. Proteins. 2004;56(4):661-8.
  1. Ramakrishna V, Vasilakos JP, Tario JD, Berger MA, Wallace PK, Keler T. Toll-like receptor activation enhances cell-mediated immunity induced by an antibody vaccine targeting human dendritic cells. J Transl Med. 2007;5(1):1-14.
آمار
تعداد مشاهده مقاله: 989
تعداد دریافت فایل اصل مقاله: 452


counter
سامانه مدیریت نشریات علمی. قدرت گرفته از سیناوب